Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IMPI-3: High vs. Standard Dose Rifampicin for Effusive Tuberculous Pericarditis
NCT04521803Phase 2Completed
- Sponsor
- University of Cape Town
- Start
- Jan 2022
- Primary completion
- Mar 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of rifampicin in Tuberculous pericarditis (TP), sponsored by University of Cape Town. Started Jan 2022; status: completed.
02
Drugs
rifampicin
03
Conditions
Tuberculous pericarditis (TP)
Beyond the preview
Go deeper on NCT04521803.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04521803.